Conceptual Approaches to the Study of Schizophrenia

  • William T. CarpenterJr.
  • Brian Kirkpatrick
  • Robert W. Buchanan
Part of the International Perspectives Series: Psychiatry, Psychology, and Neuroscience book series


In this chapter, we offer a general overview of relevant conceptual approaches to schizophrenia and illustrate their importance by discussing their application to the treatment of schizophrenia. The concepts to be presented are:
  1. 1.

    The medical model most capable of defining the range of relevant data for the care of the schizophrenic patient and the understanding of the disorder.

  2. 2.

    The syndromal nature of schizophrenia nosology.

  3. 3.

    Models of psychopathology identifying specifiable dimensions or domains of relevance to schizophrenia.

  4. 4.

    Constructs for integrating data defining natural history and course of schizophrenia.

  5. 5.

    Concepts of clinical intervention aimed at prevention of relapse.

  6. 6.

    The relevance of the above constructs for the integration of therapeutic strategies.



Negative Symptom Express Emotion Conceptual Approach Early Relapse Prolactin Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Engel GL: The need for a new medical model: a challenge for biomedicine. Science 1977;196:129–136.PubMedCrossRefGoogle Scholar
  2. 2.
    Engel GL: The clinical application of the biopsychosocial model. Am J Psychiatry 1980;137:535–544.PubMedGoogle Scholar
  3. 3.
    Carpenter WT, Heinrichs DW: Treatment relevant subtypes of schizophrenia. J Nerv Ment Dis 1981;169:113–119.PubMedCrossRefGoogle Scholar
  4. 4.
    Breier A, Wolkowitz OM, Doran AR, et al: Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987;144:1549–1555.PubMedGoogle Scholar
  5. 5.
    Goldberg SC: Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985;11:453–456.PubMedGoogle Scholar
  6. 6.
    Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440–452.PubMedGoogle Scholar
  7. 7.
    Kraepelin E: Dementia Praecox and Paraphrenia, Barclay RB (ed). Edinburgh, ES Livingston, Ltd, 1919.Google Scholar
  8. 8.
    Strauss JS, Carpenter WT, Bartko JJ: Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974;11:61–75.PubMedGoogle Scholar
  9. 9.
    Carpenter WT, Buchanan RW: Domains of psychopathology relevant to the study of etiology and treatment in schizophrenia, in Schulz SC, Tamminga CA (eds): Schizophrenia: Scientific Progress. New York, Oxford University Press, 1989, pp 13–23.Google Scholar
  10. 10.
    Kendler KS, Gruenberg AM, Tsuang MT: Psychiatric illness in first-degree relatives of schizophrenic and surgical control patients: a family study using DSM-III criteria. Arch Gen Psychiatry 1985;42:770–779.PubMedGoogle Scholar
  11. 11.
    Kendler KS, Gruenberg AM, Tsuang MT: A DSM-III family study of the nonschizophrenic psychotic disorders. Am J Psychiatry 1986;143:1098–1105.PubMedGoogle Scholar
  12. 12.
    McGuffin P, Farmer AE, Gottesman II, et al: Twin concordance for operationally defined schizophrenia. Arch Gen Psychiatry 1984;41:541–545.PubMedGoogle Scholar
  13. 13.
    Bilder RM, Sukdeb M, Rieder RO, et al: Symptomatic and neuropsychological components of defect states. Schizophr Bull 1985;11:409–417.PubMedGoogle Scholar
  14. 14.
    Andreasen NC: Positive vs negative schizophrenia: a critical evaluation. Schizophr Bull 1985;11:380–389.PubMedGoogle Scholar
  15. 15.
    Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull 1985;11:471–486.PubMedGoogle Scholar
  16. 16.
    Neuchterlein KH, Edell WS, Norris M, et al: Attentional vulnerability indicators, thought disorder and negative symptoms. Schizophr Bull 1986; 12:408–426.Google Scholar
  17. 17.
    Asarnow RF, Steffy RA, MacCrimmon DJ, et al: An attentional assessment of foster children at risk for schizophrenia. J Abnormal Psychol 1977,86:267–275.CrossRefGoogle Scholar
  18. 18.
    Erlenmeyer-Kimling L: Biological markers for the liability to schizophrenia. Presented at the Dahlen Workshop on Biological Perspectives in Schizophrenia. Berlin, October, 1986.Google Scholar
  19. 19.
    Erlenmeyer-Kimling L, Cornblatt B, Friedman D, et al: Neurological, electrophysiological, and attentional deviations in children at risk for schizophrenia, in Henn FA, Nasrallah HA (eds): Schizophrenia As A Brain Disease. New York, Oxford University Press, 1982, pp 61–98.Google Scholar
  20. 20.
    Neuchterlein KH, Dawson ME: Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984;10:160–203.Google Scholar
  21. 21.
    Rosvold HE, Mirsky A, Sarason I, et al: A continuous performance test of brain damage. J Consult Psych 1956;20:343–350.CrossRefGoogle Scholar
  22. 22.
    Singer MT, Wynne LC, Toohey ML: Communication disorders and the families of schizophrenics, in Wynne LC, Cromwell RL, Matthysse S (eds): The Nature of Schizophrenia. New York, John Wiley & Sons, 1978, pp 499–511.Google Scholar
  23. 23.
    Buchanan RW, Heinrichs DW, Kirkpatrick B: Neurological signs in schizophrenia. Presented at the International Congress on Schizophrenia Research, Clearwater, Florida, March, 1987.Google Scholar
  24. 24.
    Thaker G, Buchanan RW, Kirkpatrick B, et al: Eye movements in schizophrenia: clinical and neurobiological correlates. Abstracts of the Society for Neuroscience, 1988;14:141.2.Google Scholar
  25. 25.
    World Health Organization: The International Pilot Study of Schizophrenia, Vol. 1. Geneva, World Health Organization, 1973.Google Scholar
  26. 26.
    Harding CM, Brooks GW, Ashikaga T, et al: The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. Am J Psychiatry 1987;144:718–726.PubMedGoogle Scholar
  27. 27.
    Harding CM, Brooks GW, Ashikaga T, et al: The Vermont longitudinal study of persons with severe mental illness, II: Longterm outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 1987;144:727–735.PubMedGoogle Scholar
  28. 28.
    McGlashan TH: Selective review of recent North American follow-up studies of schizophrenia. Schizophr Bull 1988; 14(4):515–542.PubMedGoogle Scholar
  29. 29.
    Angst J: European long-term follow-up studies of schizophrenia. Schizophr Bull 1988;14(4):501–514.PubMedGoogle Scholar
  30. 30.
    Huber G, Gross C, Schuttler R: A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatrica Scand 1975;52:49–57.CrossRefGoogle Scholar
  31. 31.
    Huber G, Gross C, Schuttler R, et al: Longitudinal studies of schizophrenic patients. Schizophr Bull 1980;6(4):592–605.PubMedGoogle Scholar
  32. 32.
    Bleuler M: A 23-year longitudinal study of 208 schizophrenics and impressions in regard to the nature of schizophrenia, in Rosenthal D, Kety SS (eds): The Transmission of Schizophrenia. New York, Pergamon Press, 1968, pp 3–12.Google Scholar
  33. 33.
    Bleuler M: The Schizophrenic Disorders, Clemens SM (trans). New Haven, Yale University Press, 1978.Google Scholar
  34. 34.
    Ciompi L: Catamnestic long-term study of the course of life and aging of schizophrenics. Schizophr Bull 1980;6:606–618.PubMedGoogle Scholar
  35. 35.
    Ciompi L: Three lectures on schizophrenia. Br J Psychiatry 1980,136:413–420.PubMedCrossRefGoogle Scholar
  36. 36.
    Carpenter WT, Kirkpatrick B: The heterogeneity of long-term course of schizophrenia: implications for future research. Schizophr Bull 1988; 14(4):645–652.PubMedGoogle Scholar
  37. 37.
    Shelton RC, Weinberger DR: X-ray computed tomography studies in schizophrenia: a review and synthesis, in Nasrallah HA, Weinberger DR (eds): Handbook of Schizophrenia, vol 1. New York, Elsevier Science Publishers, 1986, pp 207–250.Google Scholar
  38. 38.
    Vaillant GE: The prediction of recovery in schizophrenia. J Nerv Ment Dis 1962;35:534–543.Google Scholar
  39. 39.
    Stephens JH: Long-term prognosis and follow-up in schizophrenia. Schizophr Bull 1978;4:25–47.PubMedGoogle Scholar
  40. 40.
    Strauss JS, Carpenter WT: The prognosis of schizophrenia, in Bellak L (ed): Disorders of the Schizophrenic Syndrome. New York, Basic Books, 1979, pp 472–491.Google Scholar
  41. 41.
    Lewine RJ, Watt NF, Prentky RA, et al: Childhood social competence in functionally disordered psychiatric patients and in normals. J Abn Psychiatry 1980;89:132–138.CrossRefGoogle Scholar
  42. 42.
    Watt N, Stolorow R, Lubensky A, et al: School adjustment and behavior of children hospitalized for schizophrenia as adults. Am J Orthopsychiatry 1970;40:637–657.PubMedCrossRefGoogle Scholar
  43. 43.
    Parnas J, Schulsinger F, Schulsinger H, et al: Behavioral precursors of schizophrenia spectrum. Arch Gen Psychiatry 1982;39:658–664.PubMedGoogle Scholar
  44. 44.
    Kendler KS, Gruenberg AM, Strauss JS: An independent analysis of the Copenhagen sample of the Danish adoption study of schizophrenia: V. The relationship between childhood social withdrawal and adult schizophrenia. Arch Gen Psychiatry 1982;39:1257–1261.PubMedGoogle Scholar
  45. 45.
    Kendler KS, Hays P: Schizophrenia with premorbid inferiority feelings. Arch Gen Psychiatry 1982;39:643–647.PubMedGoogle Scholar
  46. 46.
    McGlashan TH: Late onset improvement in schizophrenia and aging, in Miller NE, Cohen GD (eds): Chronic Schizophrenia: Characteristics and Prediction. New York, Guilford Publications, 1987, pp 61–73.Google Scholar
  47. 47.
    Andreasen NC: The diagnosis of schizophrenia. Schizophr Bull 1987;13:9–22.PubMedGoogle Scholar
  48. 48.
    Gottesman II, McGuffin P, Farmer AE: Clinical genetics as clues to the “real” genetics of schizophrenia (A decade of modest gains while playing for time). Schizophr Bull 1987;13:23–47.PubMedGoogle Scholar
  49. 49.
    Kety SS, Rosenthal D, Wender PH, et al: The types and prevalence of mental illness in the biological and adoptive families of adopted schizophrenics. J Psychiatric Res 1968;6:345–362.CrossRefGoogle Scholar
  50. 50.
    Wagman AMI, Heinrichs DW, Carpenter WT: Deficit and nondeficit forms of schizophrenia: neuropsychological evaluation. Psychiatry Res 1987;22:319–330.PubMedCrossRefGoogle Scholar
  51. 51.
    Heston LL: Psychiatric disorders in foster home reared children of schizophrenic mothers. Br J Psychiatry 1966;112:819–825.PubMedCrossRefGoogle Scholar
  52. 52.
    Leonhard K: The question of prognosis in schizophrenia. Internat J Psychiatry 1966;2:633–635.Google Scholar
  53. 53.
    Langfeldt G: Schizophrenia: diagnosis and prognosis. Behav Sci 1969;14:173–182.Google Scholar
  54. 54.
    Kleist K: Schizophrenic symptoms and cerebral pathology. J Ment Sci 1960;106:246–253.PubMedGoogle Scholar
  55. 55.
    Hawk AB, Carpenter WT, Strauss JS: Diagnostic criteria and 5-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry 1975;32:343–347.PubMedGoogle Scholar
  56. 56.
    Brockington IF, Kendell RE, Leff JP: Definition of schizophrenia: concordance and prediction of outcome. Psychol Med 1978;8:387–398.PubMedCrossRefGoogle Scholar
  57. 57.
    Kendell RE, Brockington IF, Leff JP: Prognostic implications of six alternative definitions of schizophrenia. Arch Gen Psychiatry 1979;35:25–31.Google Scholar
  58. 58.
    Flekkoy K, Lund I, Astrup C: Prolonged clinical and experimental follow-up of hospitalized schizophrenics. Neuropsychobiology 1975;1:47–58.PubMedCrossRefGoogle Scholar
  59. 59.
    Lin K, Kleinman AM: Psychopathology and clinical course of schizophrenia: a cross-cultural perspective. Schizophr Bull 1988; 14(4):555–568.PubMedGoogle Scholar
  60. 60.
    McGlashan TH: The Chestnut Lodge follow-up study: II. Long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry 1984;41:586–601.PubMedGoogle Scholar
  61. 61.
    Kane JM: Low dose medication strategies in the maintenance treatment of schizophrenia. Schizophr Bull 1983;9:528–532.PubMedGoogle Scholar
  62. 62.
    Kane JM, Rifkin A, Woerner M, et al: Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893–896.PubMedGoogle Scholar
  63. 63.
    Marder SR, Van Putten T, Mintz J, et al: Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Arch Gen Psychiatry 1987;44:518–521.PubMedGoogle Scholar
  64. 64.
    Schooler NR: Symptoms of psychopathology as predictors of relapse in schizophrenia, in Lieberman JA, Kane JM (eds): Predictors of Relapse in Schizophrenia. Washington, American Psychiatric Press, Inc, 1986, pp 33–45.Google Scholar
  65. 65.
    Heinrichs DW, Carpenter WT: Experiences with a drug-free month in schizophrenic outpatients. Psychopharmacol Bull 1985;21:117–119.PubMedGoogle Scholar
  66. 66.
    Prien RF, Cole JO, Belkin NF: Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. Br J Psychiatry 1968; 115:679–686.CrossRefGoogle Scholar
  67. 67.
    Prien RF, Levine J, Switkalski RW: Discontinuation of chemotherapy for chronic schizophrenics. HCP 1971;January:20–23.Google Scholar
  68. 68.
    Andrews P, Hall JN, Smith RP: A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br J Psychiatry 1976;128:451–455.PubMedCrossRefGoogle Scholar
  69. 69.
    Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16–21.PubMedGoogle Scholar
  70. 70.
    Koenigsberg HW, Handley R: Expressed emotion: from predictive index to clinical construct. Am J Psychiatry 1986;143:1361–1373.PubMedGoogle Scholar
  71. 71.
    Parker G, Johnston P, Hayward L: Parental ‘Expressed Emotion’ as a predictor of schizophrenic relapse. Arch Gen Psychiatry 1988;45:806–813.PubMedGoogle Scholar
  72. 72.
    Kanter J, Lamb HR, Loeper C: Expressed emotion in families: a critical review. HCP 1987;38:374–380.Google Scholar
  73. 73.
    Hogarty GE, McEvoy JP, Munetz M, et al: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 1988;45:797–805.PubMedGoogle Scholar
  74. 74.
    Lieberman JA, Kane JM, Galdaleta D, et al: Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 1984; 141:633638.Google Scholar
  75. 75.
    Van Kammen DP, Docherty JP, Bunney WE Jr: Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimo-zide treatment. Biol Psychiatry 1982;17:233–242.PubMedGoogle Scholar
  76. 76.
    Lieberman JA, Kane JM, Sarantakos S, et al: Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987;44:597–603.PubMedGoogle Scholar
  77. 77.
    Angrist B, Peselow E, Rotrosen J, et al: Relationship between responses to dopamine agonists, psychopathology, neuroleptic maintenance in schizophrenic subjects, in Angrist B, Burrows G, Lader M, et al. (eds): Recent Advances in Neuropsychopharmacology, vol. 31. New York, Pergamon Press, 1981. pp 49–54.Google Scholar
  78. 78.
    Zander K, Fischer B, Zimmer R, et al: Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal. Psychopharmacology 1981;73:43–47.PubMedCrossRefGoogle Scholar
  79. 79.
    Brown W, Laughren T: Low serum prolactin and early relapse following neuroleptic withdrawal. Am J Psychiatry 1981;138:237–239.PubMedGoogle Scholar
  80. 80.
    Lieberman JA, Kane JM, Gadaletta D, et al: Methylphenidate challenge tests and course of schizophrenia. Psychopharmacol Bull 1985;21:123–129.PubMedGoogle Scholar
  81. 81.
    Faraone SV, Curran JP, Laughren T, et al: Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction. Psychiatry Res 1986;19:311–322.PubMedCrossRefGoogle Scholar
  82. 82.
    Faraone SV, Brown WA, Laughren T: Neuroleptic bioavailability and clinical status: a two-year study of schizophrenic outpatients. J Clin Psychiatry 1987;48:151–154.PubMedGoogle Scholar
  83. 83.
    Wilkins JN, Marder SR, Van Putten T, et al: Circulating prolactin predicts risk of exacerbation in patients on depot fluphenazine. Psychopharmacol Bull 1987;23:522–525.Google Scholar
  84. 84.
    Brown GM, Cleghorn JM, Kaplan RD, et al: Longitudinal growth hormone studies in schizophrenia. Psychiatry Res 1988;24:123–136.PubMedCrossRefGoogle Scholar
  85. 85.
    Carpenter WT. Early targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 1986;47(suppl):23–29.PubMedGoogle Scholar
  86. 86.
    Baldessarini RJ, Cole JO, Davis JM, et al: Clinical indications for prolonged neuroleptic treatment. American Psychiatric Association Task Force on Tardive Dyskinesia. Washington, DC, American Psychiatric Association, 1980, pp 98–136.Google Scholar
  87. 87.
    Baldessarini RJ, Davis JM: What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 1980;3:115–122.PubMedCrossRefGoogle Scholar
  88. 88.
    Hogarty GE, Goldberg SC, Schooler NR, et al: Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two year relapse rates. Arch Gen Psychiatry 1974;31:603–608.PubMedGoogle Scholar
  89. 89.
    Davis J: Overview: maintenance therapy in psychiatry: 1. Schizophrenia. Am J Psychiatry 1975;132:1237–1245.Google Scholar
  90. 90.
    Falloon IRH, Liberman RP: Interactions between drug and psychosocial therapy in schizophrenia. Schizophr Bull 1983;9:543–554.PubMedGoogle Scholar
  91. 91.
    Goldstein MJ: Psychosocial issues. Schizophr Bull 1987;13:157–171.PubMedGoogle Scholar
  92. 92.
    Marder SR, Van Putten T, Mintz J, et al: Maintenance therapy in schizophrenia: new findings, in Kane JM (ed): Drug Maintenance Strategies in Schizophrenia. Washington, DC, American Psychiatric Press, 1984, pp 32–49.Google Scholar
  93. 93.
    Lehmann HE, Wilson WH, Deutsch M: Minimal maintenance medication: effects of three dose schedule on relapse rates and symptoms in chronic schizophrenic outpatients. Comp Psychiatry 1983;24:293–303.CrossRefGoogle Scholar
  94. 94.
    Faraone SV, Cirelli V, Curran JP, et al: Neuroleptic dose reduction for schizophrenic outpatients: a three-year follow-up study. HCP 1988,39:1207–1208.Google Scholar
  95. 95.
    Herz MI, Szymanski HV, Simon JC: Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. Am J Psychiatry 1982;139:91–922.Google Scholar
  96. 96.
    Carpenter WT, Heinrichs DW: Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 1983;9:533–542.PubMedGoogle Scholar
  97. 97.
    Herz MI, Glazer W: Intermittent medication in schizophrenia—preliminary results. Schizophr Res 1988; 1 (2–3):224–225.Google Scholar
  98. 98.
    Carpenter WT, Heinrichs DW, Hanlon T, et al: Continuous targeted medication in schizophrenia outpatients: outcome results. Schizophr Res 1988; 1(2–3): 223–224.Google Scholar
  99. 99.
    Carpenter WT, Stephens JH, Rey AC, et al: Early intervention vs continuous pharmacotherapy of schizophrenia. Psychopharm Bull 1982;18:21–23.Google Scholar
  100. 100.
    Carpenter WT, Heinrichs DW, Hanlon TE: A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987;144:1466–1470.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1990

Authors and Affiliations

  • William T. CarpenterJr.
  • Brian Kirkpatrick
  • Robert W. Buchanan

There are no affiliations available

Personalised recommendations